Active pharmaceutical absorbance

Jamali, B., and Nielsen, H. M. (2003). Development and validation of a capillary electrophoresis-indirect photometric detection method for the determination of the non-UV-absorbing 1,4-dideoxy-l,4-imino-d-arabinitol in active pharmaceutical ingredients, solutions and tablets using an internal standard. J. Chromatogr. A 996(1—2), 213-223. 

In the pharmaceutical industry, medicines are standardized to a particular weight of active pharmaceutical per unit (for example, mg of substance per tablet), so the weight of a substance in a tablet, or volume of medicine, is of more interest than the number of moles. For most pharmaceutical preparations, then, we use the specific absorbance, A(l%, 1 cm), which is the absorbance (logio fo/f) of a 1% w/v solution (i.e. 1 g of substance in 100 cm solvent) in a 1 cm path length cell, in place of the molar absorptivity, e. This is the absolute method of substance identification, and the absorbance. A, can be related to T(l%, 1 cm) by equation (2.4) ... 

Wavelength repeatability is a measure of the precision of wavelength measured. The bandwidth refers to the width of an emission band (from the monochromator) at half peak height. This value, normally provided by the manufacturer is accepted. Using a mercury vapor lamp one can also check the spectral width. A number of well defined emission lines at 243.7, 364.9, 404.5, 435.8, 546.1, 576.9, and 579 nm can be used to check spectral bandwidth. However, the accuracy of the absorbance measured is dependent on the ratio of spectral bandwidth to the normal bandwidth (NEW) of the absorbing species. Most active pharmaceutical compounds have a normal bandwidth of approximately... 

The rate and extent at which the active pharmaceutical ingredient or active moiety is absorbed from a pharmaceutical dosage form and becomes available at the site(s) of action. 

The rate and extent to which the active moiety is absorbed from a pharmaceutical dosage form and becomes available at the site(s) of action. Reliable measurements of drug concentrations at the site(s) of action are usually not possible. The substance in the general circulation, however, is considered to be in equilibrium with the substance at the site(s) of action. Bioavailability can be therefore defined as the rate and extent to which the active pharmaceutical ingredient or active moiety is absorbed from a pharmaceutical dosage form and becomes available in the general circulation. Based on pharmacokinetic and clinical considerations it is generally accepted that in the same subject an essentially similar plasma concentration time course will result in an essentially similar concentration time course at the site(s) of action. 

Extraction of activated carbons by a multiple treatment with a mixture of azeotropic hydrochloric acid and distilled water and large-scale production of high-purity activated carbon absorbents have been successfully applied to wastewater treatment and water purification and pharmaceutical and medical preparations. 

Many pharmaceutical compounds contain chromophores that make them suitable for analysis by UV/Vis absorption. Products that have been analyzed in this fashion include antibiotics, hormones, vitamins, and analgesics. One example of the use of UV absorption is in determining the purity of aspirin tablets, for which the active ingredient is acetylsalicylic acid. Salicylic acid, which is produced by the hydrolysis of acetylsalicylic acid, is an undesirable impurity in aspirin tablets, and should not be present at more than 0.01% w/w. Samples can be screened for unacceptable levels of salicylic acid by monitoring the absorbance at a wavelength of... 

The rationale for the development of such fibers is demonstrated by their appHcation in the medical field, notably hemoperfusion, where cartridges loaded with activated charcoal-filled hoUow fiber contact blood. Low molecular weight body wastes diffuse through the fiber walls and are absorbed in the fiber core. In such processes, the blood does not contact the active sorbent direcdy, but faces the nontoxic, blood compatible membrane (see Controlled RELEASE TECHNOLOGY, pharmaceutical). Other uses include waste industrial appHcations as general as chromates and phosphates and as specific as radioactive/nuclear materials. 

BioavaUabUity and bioequivalence are related terms but they can be confused. Bioavailabihty as defined earlier is also known as absolute bioavailability and is simply the fraction of the administered dose that reaches the systemic circulation it is therefore defined only in terms of the extent of drug absorption. However, in the Committee for Proprietory Medicinal Products (CPMP) guideline for the investigation of bioavailability and bioequivalence, the former is defined as the rate and extent to which the active substance of therapeutic moiety is absorbed from a pharmaceutical form and becomes available at the site of action. The reason that bioavailability has been defined in this way is because rate, as well as extent, is important when comparing the bioavailability of two pharmaceutical forms of an active substance to determine whether they are bioequivalent. Bioequivalence and comparative bioavaUabUity are discussed later but absolute bioavailabihty will be described first. 

Since the first series of compounds were poorly soluble in water, the next crucial phase of the project set out to increase the water solubility of the drug candidates in order to increase absorption from the gastrointestinal tract. Further refinements led to a candidate that was not only well absorbed when administered orally to animals, but also had outstanding antimalarial profiles both in vitro and in vivo. In comparison to available semi-synthetic artemisinins, the drug candidate OZ 277 (Scheme 27) exhibits structural simplicity, an economically feasible and scalable synthesis, superior antimalarial activity and an improved pharmaceutical profile. The toxicological profiles are also acceptable and this drug candidate entered first into man studies during 2004. 

Although the development segment of pharmaceutical research has a lesser scientific component than the discovery phase, it remains a substantial undertaking that absorbs more than half of total industry research budgets. Cockburn and Henderson (2001, p. 6) report that the relative cost of development efforts has accounted for between 60% and 70% of pharmaceutical research activities since 1970. The costs of this work are largely determined by FDA requirements. 

Bioavailability According to the European Medicines Evaluation Agency (EMEA), bioavailability (F%) is the rate and extent to which an active moiety is absorbed from a pharmaceutical form, and becomes available in the systemic circulation. As a parameter, there are two types of bioavailability ... 

---